Get the Stockscreener App
2.11
6.57%
0.13
Vivosim Labs Inc stock is traded at $2.11, with a volume of 46,079.
It is up +6.57% in the last 24 hours and up +6.03% over the past month.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
See More
Previous Close:
$1.98
Open:
$1.95
24h Volume:
46,079
Relative Volume:
0.78
Market Cap:
$5.49M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+19.21%
1M Performance:
+6.03%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$1.95
$2.17
1-Week Range:
$1.7239
$2.17
52-Week Range:
$1.41
$2.37
Vivosim Labs Inc Stock (VIVS) Company Profile
Name
Vivosim Labs Inc
Sector
Industry
Phone
858-224-1000
Address
11555 SORRENTO VALLEY ROAD, SAN DIEGO
Compare VIVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VIVS
Vivosim Labs Inc
|
2.11 | 4.71M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Vivosim Labs Inc Stock (VIVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-18 | Initiated | H.C. Wainwright | Buy |
| Nov-10-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-25-17 | Initiated | Raymond James | Outperform |
| Aug-11-15 | Downgrade | Cantor Fitzgerald | Buy → Hold |
| Jun-29-15 | Initiated | Jefferies | Buy |
| Jun-29-15 | Initiated | Piper Jaffray | Overweight |
View All
Vivosim Labs Inc Stock (VIVS) Latest News
Sector ETF performance correlation with VivoSim Labs Inc.Earnings Growth Summary & Long-Term Safe Return Strategies - Newser
Is a relief rally coming for VivoSim Labs Inc. holdersMarket Activity Report & Low Risk Entry Point Guides - Newser
Forecasting VivoSim Labs Inc. price range with options dataPortfolio Risk Summary & Fast Moving Trade Plans - Newser
How to track smart money flows in VivoSim Labs Inc.July 2025 Snapshot & Free Real-Time Market Sentiment Alerts - Newser
Can swing trading help recover from VivoSim Labs Inc. losses2025 Big Picture & Entry and Exit Point Strategies - Newser
Real time pattern detection on VivoSim Labs Inc. stock2025 Big Picture & Technical Confirmation Alerts - Newser
Can VivoSim Labs Inc. rally from current levelsSwing Trade & Risk Managed Investment Strategies - Newser
Is VivoSim Labs Inc. stock poised for growth2025 Geopolitical Influence & Low Risk High Reward Ideas - Newser
Is it time to cut losses on VivoSim Labs Inc.July 2025 Retail & AI Enhanced Trade Execution Alerts - Newser
Chart based analysis of VivoSim Labs Inc. trendsM&A Rumor & Safe Entry Trade Reports - Newser
Risk vs reward if holding onto VivoSim Labs Inc.2025 Pullback Review & Accurate Intraday Trading Signals - Newser
Statistical indicators supporting VivoSim Labs Inc.’s strength2025 Market Overview & Expert Curated Trade Ideas - Newser
Will a bounce in VivoSim Labs Inc. offer an exitQuarterly Earnings Report & AI Based Buy/Sell Signal Reports - Newser
Can VivoSim Labs Inc. recover in the next quarterTrade Analysis Report & Long-Term Safe Return Strategies - Newser
Will VivoSim Labs Inc. stock recover after recent drop2025 Market Trends & Daily Growth Stock Investment Tips - Newser
Signal strength of VivoSim Labs Inc. stock in tech scannersQuarterly Market Review & Fast Gain Swing Alerts - Newser
Visual analytics tools that track VivoSim Labs Inc. performanceMarket Weekly Review & Low Risk Growth Stock Ideas - Newser
Is VivoSim Labs Inc. stock ready for a breakoutQuarterly Earnings Report & Real-Time Volume Trigger Notifications - Newser
Detecting price anomalies in VivoSim Labs Inc. with AIPortfolio Performance Summary & AI Driven Price Forecasts - Newser
Quantitative breakdown of VivoSim Labs Inc. recent moveJuly 2025 Pullbacks & Weekly High Potential Stock Alerts - Newser
Understanding VivoSim Labs Inc.’s price movementNew Guidance & Verified Momentum Watchlists - Newser
VivoSim Labs Appoints New Chief Commercial Officer - MSN
VivoSim appoints Lialin as Chief Commercial Officer - MSN
Is it too late to sell VivoSim Labs Inc.Portfolio Performance Summary & Real-Time Volume Spike Alerts - Newser
Published on: 2025-08-17 01:20:17 - Newser
Why VivoSim Labs Inc. stock attracts strong analyst attention2025 Stock Rankings & Smart Allocation Stock Reports - sundaytimes.kr
What institutions are buying VivoSim Labs Inc. stock nowGap Down & AI Based Trade Execution Alerts - beatles.ru
What are some under 2 biotech ticker? Give their plans - AInvest
Real time scanner hits for VivoSim Labs Inc. explained2025 Retail Activity & Low Drawdown Investment Strategies - Newser
What risks could impact VivoSim Labs Inc. stock performance2025 Winners & Losers & Weekly Consistent Profit Watchlists - Newser
How to forecast VivoSim Labs Inc. trends using time seriesQuarterly Profit Review & Stock Portfolio Risk Control - Newser
Vivosim Labs Inc Stock (VIVS) Financials Data
There is no financial data for Vivosim Labs Inc (VIVS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):